| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 150,950 | 6,197 |
| Net change in cash, cash equivalents, and restricted cash | -111,451 | -129,043 |
| Cash and cash equivalents at beginning of period | 196,538 | - |
| Cash and cash equivalents at end of period | 85,087 | - |
Prime Medicine, Inc. (PRME)
Prime Medicine, Inc. (PRME)